Tobin Schilke - Dec 15, 2021 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: CFO
Signature: /s/ Terri McDowell, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: Dec 15, 2021
Transactions value $: -$24,772
Form type: 4
Date filed: 12/17/2021, 04:31 PM
Previous filing: Jul 2, 2021
Next filing: Jan 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	-$24.8K	-1.56K	-2.25%	$15.92	67.7K	Dec 15, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of 4,500 shares of a Restricted Stock award ("RSA") for 18,000 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.

Content

Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of 4,500 shares of a Restricted Stock award ("RSA") for 18,000 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.